increases the uterine artery endothelial expression of cPLA 2 , COX-1, and PGIS, which leads to increases of the stable PGI 2 metabolite, 6-keto-Prostaglandin F1α (6-keto-PGF1α). 7, 12, 13 In human umbilical vein endothelial cells (HUVECs), E 2 β has also been shown to selectively stimulate PGI 2 production in vitro primarily via ER-α. 14 However, less is known about the influence of E 2 β on endothelial TXA 2 production and on the endothelial PGI 2 /TXA 2 ratio.
The stimulatory effects of estrogen on uterine vascular endothelial PGI 2 production may be further modulated by its biologically active metabolites. E 2 β is sequentially metabolized by cytochrome P450s to form the catecholestradiols, 2-hydroxyestradiol (2-OHE 2 ) and 4-hydroxyestradiol (4-OHE 2 ), followed by metabolism of these catecholestradiols by catechol-O-methyltransferase to form 2-methoxyestradiol (2-ME 2 ) and 4-methoxyestradiol (4-ME 2 ). [15] [16] [17] [18] In cultured HUVECs, 2-ME 2 stimulates production of PGI 2 . 19 Despite this knowledge, very little is known about the effects of E 2 β metabolites on endothelial PGI 2 levels. Furthermore, nothing is known about the roles of the classical ERs on E 2 β metabolite-induced endothelial PGI 2 levels. It is also unclear whether E 2 β metabolites can alter TXA 2 production and the PGI 2 / TXA 2 ratio in endothelial cells and whether this is altered in pregnancy.
Thus, we hypothesized that E 2 β and its metabolites, 2-OHE 2 , 4-OHE 2 , 2-ME 2 and 4-ME 2 , can augment the PGI 2 /TXA 2 ratio via ER-α and ER-β, through the classical cPLA 2 -COX-1-PGIS pathway in uterine artery endothelial cells (UAECs) in the pregnant (P-UAECs) compared with UAECs in the nonpregnant (NP-UAECs) state. Thus, we investigated: (1) the expression of cPLA 2 , COX-1, PGIS, and TXAS in P-UAECs versus NP-UAECs; (2) whether treatment with E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 or 4-ME 2 can increase the PGI 2 /TXA 2 ratio in P-UAECs more than NP-UAECs; (3) the role of COX-1 and PGIS in regulating P-UAEC PGI 2 levels; and (4) the roles of ER-α and ER-β on PGI 2 levels induced by E 2 β and its metabolites.
Methods

Cell Preparation and Culture
Animal use protocols and procedures were approved by the University of Wisconsin-Madison School of Medicine Research Animal Care Committee. Ovine NP-UAECs and P-UAECs were isolated, validated, and cultured from nonpregnant (luteal n=2 and follicular n=2) and late gestation (120-130 days; term, 147 days; n=4) ewes as previously described. 6, 17, 18 At passage 4 and ≈70% confluence and serumstarved (24 hours), cells were lysed for Western blotting or transferred to 6-well plates for treatments as needed for respective experiments.
Protein Extraction and Western Immunoblotting
Protein extraction and Western Immunoblot analyses were performed as described previously. 6, 17, 18 cPLA 2 , COX-1, PGIS, and TXAS expressions were detected using mouse anti-cPLA 2 , rabbit anti-COX-1, rabbit anti-PGIS, or rabbit anti-TXAS (1:1000) and respective secondary antibodies (1:2000) . β-actin was used as loading control. Positive control was only used for the expression of TXAS using human platelet lysates. Human platelet lysates were a generous donation from the Platelet and Neutrophil Immunology Laboratory, Blood Center of Wisconsin.
Experimental Treatments, Blockade of Enzymes and Receptors
All experiments were performed in quadruplicate and replicated in at least 4 different P-UAEC (n=4) and NP-UAEC (n=4) preparations. For time and concentration-response studies, P-UAECs in 6-well plates were serum-starved (24 hours) in Endothelial Basal Medium (EBM), washed with serum-free EBM, and the medium was replaced with EBM vehicle (Control) or EBM containing 0.1, 1, 10, or 100 nmol/L of E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , 4-ME 2 , or Ca 2+ Ionophore (A23187; positive control) for 0, 2, 4, 8, 12, or 24 hours. For nonpregnant versus pregnant concentration-response studies, NP-UAECs and P-UAECs in 6-well plates were serum-starved (24 hours) in EBM, washed with serum-free EBM, and medium was replaced with EBM vehicle (Control) or EBM containing 0.1, 1, 10, or 100 nmol/L of E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , 4-ME 2 , or A23187 for 12 hours based on time course studies. COX-1 or PGIS blockade was performed by pretreating P-UAECs with SC-560 and U-51605 (1 μmol/L, 1 hour), respectively, followed by E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , 4-ME 2 , or A23187 treatments at optimal dose (determined from concentration-response curves). ERs were E 2 β indicates estradiol-17β; UAEC, uterine artery endothelial cells; NP-UAEC, UAECs in the nonpregnant; P-UAEC, UAECs in the pregnant; 2-OHE 2 , 2-hydroxyestradiol; 4-OHE 2 , 4-hydroxyestradiol; 2-ME 2 , 2-methoxyestradiol; and 4-ME 2 , 4-methoxyestradiol. A higher concentration-dependent increase in the PGI 2 /TXA 2 ratio was observed in P-UAECs with E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 treatments compared with NP-UAECs.
*Increases (P<0.05; n=4) in UAEC PGI 2 /TXA 2 ratios compared with untreated controls. †Increases (P<0.05; n=4) in P-UAEC PGI 2 /TXA 2 ratios compared with respective NP-UAECs group at specified concentration.
by guest on September 13, 2017 http://hyper.ahajournals.org/ Downloaded from blocked by pretreating P-UAECs for 1 hour with 1 µmol/L of the nonselective ER antagonist ICI 182 780, ER-α-selective antagonist 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinyleth oxy)phenol]-1H-pyrazole dihydrochloride (MPP), or the ER-β-selective antagonist 4-[2-phenyl-5,7-bis (trifluoromethyl) pyrazolo [1,5-a] pyrim idin-3-yl]phenol (PHTPP) followed by treatments with EBM vehicle or EBM containing 0.1, 1, 10, or 100 nmol/L of E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , 4-ME 2 , or A23187 for optimal time determined from time courses.
PGI 2 and TXA 2 Assays
After steroid treatments, media from individual 6-well plates were collected to measure production levels of PGI 2 or TXA 2 by using enzyme immunoassay kits (Cayman Chemical, Ann Arbor, MI). Indices of both PGI 2 and TXA 2 levels were calculated from measuring their stable nonenzymatic hydrolysis products, 6-keto-PGF1α and thromboxane B 2 (TXB 2 ), respectively, in duplicates. Productions were calculated per manufacturer's instructions after subtracting the value of the blank wells to remove background absorbance values. The levels of PGI 2 or TXA 2 in NP-UAECs and P-UAECs are expressed as the fold or ratio increases over untreated control in pg/mL corrected against a standard curve, nonspecific binding, maximum binding and normalized to the amount of protein per well in mg.
Statistical Analysis
Data are presented as a fold change of untreated control and expressed as means±SEM. For the PGI 2 /TXA 2 ratio, data are presented as the ratio of PGI 2 /TXA 2 calculated from the absolute pg/mL concentrations from the same treatment wells in duplicates from all cell lines studied. Data were analyzed using a 2-way ANOVA (SigmaPlot 11 Statistical Software). When appropriate, an analysis of the simple effect was performed using 1-way ANOVA followed by post hoc Student-Newman-Keuls test. Pairwise comparisons were performed using Student-Newman-Keuls test. Level of significance was established a priori at P<0.05.
Results
Expression of cPLA 2 , COX-1, PGIS, and TXAS in NP-UAECs Versus P-UAECs
Western immunoblotting revealed the protein expression of cPLA 2 , COX-1, PGIS, and TXAS in both NP-UAECs and P-UAECs ( Figure 1A ). Densitometric analyses showed that the protein expressions of cPLA 2 , COX-1, and PGIS were significantly higher in P-UAECs compared with NP-UAECs ( Figure 1B ). In contrast, the expression of TXAS was significantly reduced in P-UAECs compared with NP-UAECs ( Figure 1B ).
Basal and Calcium Ionophore Stimulated PGI 2 and TXA 2 Production in NP-UAECs and P-UAECs
Basal production of PGI 2 was higher by P-UAECs compared with NP-UAECs (Figure 2A ). Unstimulated basal production of PGI 2 by P-UAECs at 8, 12, and 24 hours was 1.31±0.23-, 1.43±0.23-, and 1.53±0.23-fold, respectively, corresponding to 47±0.75, 58±0.70, and 68±0.16 pg/mg of protein, respectively, at the same time points. A23187 stimulated significant production of PGI 2 in P-UAECs compared with NP-UAECs ( Figure 2B ). Maximum production by P-UAECs at 12 hours was 10.8±0.39-fold of control compared with maximum production by NP-UAECs of 6.0±0.37-fold of control.
Basal production of TXA 2 by P-UAECs was not different compared with production by NP-UAECs ( Figure 2C ). Unstimulated basal production of TXA 2 by P-UAECs at 8, 12, and 24 hours was 1.18±0.19-, 1.20±0.19-, 1.33±0.36-fold, respectively, corresponding to 13±1.0, 20±1.1, and 23±0.22 pg/ mg of protein, respectively, at the same time points. However, A23187 stimulated significantly lower concentration-dependent production of TXA 2 in P-UAECs compared with NP-UAECs ( Figure 2D ). The maximum production by P-UAECs at 12 hours was 1.49±0.09-fold of control compared with maximum production by NP-UAECs at 1.93±0.64-fold of control. E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 Stimulated a Time-and Concentration-Dependent PGI 2 
Increase in P-UAECs
Time-and concentration-dependent PGI 2 increases were observed in P-UAECs after E 2 β treatment with highest responses observed at a concentration of 100 nmol/L at 12 hours treatment time ( Figure 3A ). Increases of PGI2 were noted after 4 hours in response to almost all concentration of E 2 β studied with the exception of 0.1 nmol/L. However, at 4, 8, 12, 24 hours, there were significant differences in PGI 2 levels in response to 10 and 100 nmol/L E 2 β which were higher compared with 0.1 or 1 nmol/L concentrations. Similarly, exposure of P-UAECs to 2-OHE 2 and 4-OHE 2 treatments also stimulated a time-and concentration-dependent PGI 2 increases by P-UAECs with maximum responses observed at a concentration of 100 nmol/L at 12 hours of treatment ( Figure 3B and 3C). Nevertheless, PGI 2 increases were noted after 4 hours in response to all concentration of 2-OHE 2 and 4-OHE 2 studied, and this increased in a time-and concentration-dependent manner compared with untreated control. No further increases in 2-OHE 2 -and 4-OHE 2 -induced PGI 2 responses by P-UAECs were seen after 12 hours at all concentrations studied. There were significant differences in PGI 2 increases in response to 10 and 100 nmol/L of 2-OHE 2 and 4-OHE 2 , which were higher compared with 0.1 or 1 nmol/L concentrations at 2, 4, 8, 12, and 24 hours. However, 0.1 or 1 nmol/L concentrations stimulated significant increases of PGI 2 compared with untreated control at 2, 4, 8, 12, and 24 hours.
The time course and concentration responses of PGI 2 levels in P-UAECs induced by 2-ME 2 and 4-ME 2 are shown in Figure 3D and 3E. Both methoxyestradiols increased PGI 2 in a time-and concentration-dependent manner, with maximal effects observed at a concentration of 100 nmol/L at 12 hours of treatment. However, increases of PGI 2 by P-UAECs were seen at all concentrations studied at 2 hours of treatment time or greater. There were significant differences in PGI 2 increases in response to 1, 10, and 100 nmol/L of 2-ME 2 and 4-ME 2 , which were higher compared with 0.1 nmol/L concentration at 4 hours of treatment or greater. E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 Stimulated a Greater Concentration-Dependent PGI 2 Increase by P-UAECs More Than NP-UAECs A concentration-dependent increase in production of PGI 2 was observed by P-UAECs after E 2 β treatment with highest responses observed at a concentration of 100 nmol/L ( Figure  4A ). On the contrary, E 2 β also induced PGI 2 increases by NP-UAECs, however the increase by NP-UAECs was significantly less compared with P-UAECs and no further concentration response was observed after the 10 nmol/L concentration ( Figure 4A ). Differences in PGI 2 increases between NP-UAECs and P-UAECs were observed at 1 nmol/L, 10 nmol/L, 100 nmol/L, and 1 µmol/L concentrations.
Similar to E 2 β, 2-OHE 2 and 4-OHE 2 treatments also stimulated greater concentration-dependent PGI 2 production increases by P-UAECs compared with NP-UAECs ( Figure 4B and 4C). Maximum responses were observed at a concentration of 100 nmol/L, with no further increases seen with higher concentrations. 2-OHE 2 and 4-OHE 2 treatments did stimulate elevations of the production of PGI 2 in NP-UAECs; however, these responses were significantly lower compared with the P-UAEC responses, with no further increases seen after the 10 nmol/L concentration.
2-ME 2 and 4-ME 2 treatments also stimulated greater concentration-dependent PGI 2 production increases by P-UAECs compared with NP-UAECs ( Figure 4D and 4E). Maximum responses of P-UAECs to 2-ME 2 were seen at 100 nmol/L, with no further increases at greater doses. On the contrary, 4-ME 2 induced maximum PGI 2 production increases by P-UAECs at a concentration of 10 nmol/L,with no significant further increases with higher concentrations. Interestingly, 4-ME 2 was the only estrogen metabolite that stimulated a difference in PGI 2 production responses between NP-UAECs and P-UAECs at a concentration as low as 0.1 nmol/L. Elevated PGI 2 production was also noted by NP-UAECs in response to 2-ME 2 and 4-ME 2 ; however, these responses were of lower magnitude compared with P-UAEC responses, with no further increases seen after the 10 nmol/L concentration. and thromboxane (TXA 2 ) production by uterine artery endothelial cells derived from the nonpregnant state (NP-UAECs) and UAECs derived from the pregnant state (P-UAECs). A, Basal production of PGI 2 by P-UAECs was higher compared with NP-UAECs. B, The calcium ionophore (A23187) stimulated more production of PGI 2 in P-UAECs compared with NP-UAECs. C, Basal production of TXA 2 was not different in P-UAECs compared with NP-UAECs. D, A23187 stimulated more production of TXA 2 in NP-UAECs compared with P-UAECs. *Increases in TXA 2 production (P<0.05; n=4) compared with untreated control and time 0. †Increases in TXA 2 production (P<0.05; n=4) compared with respective P-UAEC group at specified concentrations.
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The levels of TXA 2 production stimulated by E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 increased linearly but did not reach statistical significance compared with untreated control in either NP-UAECs or P-UAECs. Therefore, these TXA 2 productions are discussed within the context of the PGI 2 /TXA 2 ratio.
The PGI 2 /TXA 2 Ratio: E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 Stimulated a Greater Concentration-Dependent PGI 2 /TXA 2 Ratios in P-UAECs More Than NP-UAECs As illustrated in the Table, the basal PGI 2 /TXA 2 ratio was higher in P-UAECs compared with NP-UAECs at 12 hours treatment. There was a concentration-dependent increase in the PGI 2 /TXA 2 ratio when P-UAECs were exposed to E 2 β and its metabolites. E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 Stimulated De Novo PGI 2 Increases in P-UAECs via COX-1 and PGIS Antagonism with the COX-1 inhibitor SC-560 and the PGIS inhibitor U-51605 was tested at all concentrations (0.1, 1, 10, and 100 nmol/L) of E 2 β and its metabolites studied; however, because all concentrations yielded similar results; only the responses from the optimal concentration of 100 nmol/L at 12 hours of treatment are shown here. Neither SC-560 nor U-51605 (1 μmol/L, 1 hour) pretreatments significantly altered basal control PGI 2 increases in P-UAECs ( Figure 5A and 5B). However, both antagonists completely abrogated the PGI 2 increases in P-UAECs stimulated by 100 nmol/L of E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , 4-ME 2 , and the Ca 2+ Ionophore (A23187; data not shown), indicating that the PGI 2 increases seen is de novo via the activities of COX-1 and PGIS ( Figure  5A and 5B).
E 2 β, but Not its Metabolites, Stimulated PGI 2 Production in P-UAECs via the Classic ERs
Antagonism with ICI 182 780 was tested at 0.1, 1, 10, and 100 nmol/L of E 2 β and its metabolites studied; however, because all concentrations yielded similar results, only the responses from the optimal concentration of 100 nmol/L are shown. Furthermore, because the NP-UAECs exhibited lower nonsignificant responses, antagonism studies were only carried out in P-UAECs. ICI 182 780 alone did not affect basal PGI 2 production in P-UAECs; however, it totally abrogated PGI 2 increases in response to E 2 β, indicating possible involvement of either ER-α and ER-β ( Figure 6 ). In contrast, ICI 182 780 did not have an effect on P-UAEC PGI 2 increases in response to 2-OHE 2 , 4-OHE 2 , 2-ME 2 , or 4-ME 2 , indicating ER-independent mechanisms. ICI 182 780 did not have an effect on PGI 2 production by P-UAECs in response to nonreceptor stimulation with A23187 (data not shown), validating specific ER-mediated E 2 β responses ( Figure 6 ). Figure 3 . Estradiol-17β and its metabolites-induced time-and concentration-dependent increases in prostacyclin production by uterine artery endothelial cells derived from the pregnant state (P-UAECs). Time-and concentration-dependent prostacyclin (PGI 2 ) production by P-UAECs in response to (A) E 2 β, (B) 2-hydroxyestradiol (2-OHE 2 ), (C) 4-hydroxyestradiol (4-OHE 2 ), (D) 2-methoxyestradiol (2-ME 2 ), and (E) 4-methoxyestradiol (4-ME 2 ). Time-and concentration-dependent PGI 2 production responses were observed in P-UAECs in response to E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 . *Increases (P<0.05; n=4) in P-UAEC PGI 2 production compared with untreated control and time 0. †Increases in P-UAEC PGI 2 production compared with respective 0.1 and 1 nmol/L (P<0.05; n=4) group at specified times. by guest on September 13, 2017 http://hyper.ahajournals.org/ Downloaded from February 2013 E 2 β, but Not its Metabolites, Stimulated PGI 2 
Production in P-UAECs Selectively via ER-α and Independent of ER-β
Similar to ICI 182 780 studies, antagonism with MPP and PHTPP were tested at all concentrations (0.1, 1, 10, and 100 nmol/L) of E 2 β and its metabolites studied. All concentrations examined yielded similar results; therefore, only the data from the optimal concentration of 100 nmol/L are shown. In P-UAECs, ER-α blockade with 1 µmol/L of MPP completely abolished the PGI 2 increases stimulated by 100 nmol/L of E 2 β indicating a role for ER-α ( Figure 7A ). In contrast, MPP did not abrogate the PGI 2 increases stimulated by 100 nmol/L of 2-OHE 2 , 4-OHE 2 , 2-ME 2 , or 4-ME 2 similar to the above ICI 182 780 ( Figure 7A ). Moreover, E 2 β-induced PGI 2 -11 -10 -9 -8 -7 
Concentration-dependent cell prostacyclin (PGI 2 ) production by NP-UAECs and P-UAECs to responses (A) E 2 β, (B) 2-hydroxyestradiol (2-OHE 2 ), (C) 4-hydroxyestradiol (4-OHE 2 ), (D) 2-methoxyestradiol (2-ME 2 ), and (E) 4-methoxyestradiol (4-ME 2 )
. Concentration-dependent responses at 12 hours were observed in P-UAECs in response to E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 ; NP-UAECs exhibited lower PGI 2 production. *Increases (P<0.05; n=4) in UAEC PGI 2 production compared with untreated control. †Increases in P-UAEC PGI 2 production compared with respective NP-UAEC (P<0.05; n=4) group at specified concentration. production by uterine artery endothelial cells derived from the pregnant state (P-UAECs) via cyclooxygenase-1 (COX-1) and prostacyclin synthase (PGIS). A, The effects of the COX-1 antagonist SC-560 (1 µmol/L) on P-UAEC PGI 2 increases in response to 100 nmol/L of E 2 β, 2-hydroxyestradiol (2-OHE 2 ), 4-hydroxyestradiol (4-OHE 2 ), 2-methoxyestradiol (2-ME 2 ), and 4-methoxyestradiol (4-ME 2 ). SC-560 abrogated PGI 2 increases by P-UAECs in response to E 2 β and its metabolites, respectively. B, The effects of the PGIS antagonist U-51605 (1 µmol/L) on P-UAEC PGI 2 increases to 100 nmol/L of E 2 β, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 . U-51506 abrogated PGI 2 increases by P-UAECs in response to E 2 β and its metabolites, respectively. *Increases (P<0.05; n=4) in P-UAEC PGI 2 production compared with untreated control. †Indicates inhibition (P<0.05; n=4) of P-UAEC PGI 2 production with inhibitor.
by guest on September 13, 2017 http://hyper.ahajournals.org/ Downloaded from production responses were not inhibited by 1 µmol/L of the ER-β-selective antagonist PHTPP, demonstrating a lack of requirement for ER-β in these responses ( Figure 7B ). Similar to MPP, PHTPP did not inhibit the PGI 2 production stimulated by 100 nmol/L of 2-OHE 2 , 4-OHE 2 , 2-ME 2 , or 4-ME 2 ( Figure  7B ). Both MPP and PHTPP did not inhibit PGI 2 production by P-UAECs induced by the nonreceptor stimulation using Ca 2+ Ionophore (A23187; data not shown), further validating specific ER-α mediated E 2 β responses.
Discussion
The key findings observed from this study are as follows: (1) Pregnancy induces higher protein expression of cPLA 2 , COX-1, and PGIS in P-UAECs compared with NP-UAECs as well as a lower protein expression of TXAS in P-UAECs compared with NP-UAECs; (2) E 2 β and its metabolites, 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 , stimulate time-and concentration-dependent increases in PGI 2 production by P-UAECs; (3) E 2 β and its metabolites stimulate a concentration-dependent increase in the PGI 2 /TXA 2 ratio more in P-UAECs compared with NP-UAECs; (4) E 2 β and its metabolites stimulate de novo PGI 2 production by P-UAECs via activities of COX-1 and PGIS; and (5) E 2 β-induced PGI 2 production by P-UAECs is mediated primarily via ER-α and independent of ER-β, whereas 2-OHE 2 , 4-OHE 2 , 2-ME 2 , and 4-ME 2 stimulate PGI 2 production in P-UAECs independent of either ER-α or ER-β.
We demonstrate herein that P-UAECs highly express the prostanoid system enzymes including cPLA 2 , COX-1, and PGIS. These data are consistent with reports of increased expression of these enzymes in ovine uterine arteries in vivo and ex vivo 6, 13, 20, 21 and shows that the elevated expression during gestation is maintained to a great extent even through passaging in culture. However, in the present study we demonstrate, for the first time, that TXAS is expressed in UAECs and that expression is lower in P-UAECs compared with NP-UAECs. Taken together, these data from our studies suggest that during pregnancy, the prostanoid enzyme system shifts its expression pattern in favor of more PGI 2 production and less TXA 2 production in support of rises and maintenance of uterine blood flow. These results demonstrate that PGI 2 production by P-UAECs is induced by gestational programming at the level of increased endothelial cell signaling, supporting earlier reports that pregnancy-specific programming in P-UAECs leads to increased basal and agonist-mediated responsiveness. 6 The retention of programming in P-UAECs, perhaps via epigenetic mechanisms, may also be responsible No ICI ICI
Figure 6. Estradiol-17β but not its metabolites stimulated prostacyclin (PGI 2 ) production by uterine artery endothelial cells derived from the pregnant state (P-UAECs) via the classic estrogen receptors (ERs). The effects of 1 µmol/L of ICI 182,780 (ICI) on P-UAEC PGI 2 production in response to 100 nmol/L of E 2 β, 2-hydroxyestradiol (2-OHE 2 ), 4-hydroxyestradiol (4-OHE 2 ), 2-methoxyestradiol (2-ME 2 ), and 4-methoxyestradiol (4-ME 2 ). ICI abrogated PGI 2 increases by P-UAECs in response to E 2 β, but not in response to 2-OHE 2 , 4-OHE 2 , 2-ME 2 , or 4-ME 2 . *Increases (P<0.05; n=4) in P-UAEC PGI 2 increases compared with untreated control. †Indicates inhibition (P<0.05; n=4) of P-UAEC PGI 2 increases with ICI. µmol/L) on P-UAEC PGI 2 production to 100 nmol/L of E 2 β, 2-hydroxyestradiol (2-OHE 2 ), 4-hydroxyestradiol (4-OHE 2 ), 2-methoxyestradiol (2-ME 2 ), and 4-methoxyestradiol (4-ME 2 ). MPP abrogated the rises in PGI 2 production by P-UAECs to E 2 β, but not in response to its metabolites. B, for elevated responses to steroids in subsequent pregnancies in vivo. 22 We also show herein that the calcium ionophore (A23187) induces significant increases of PGI 2 production by P-UAECs and TXA 2 by NP-UAECs demonstrating that the prostanoid enzymes expressed in these endothelial cells are functional and capable of eliciting calcium-dependent and receptor-independent PGI 2 and TXA 2 production. In this study, we demonstrate that E 2 β induces concentration-dependent increases of PGI 2 and PGI 2 /TXA 2 ratios more in P-UAECs than in NP-UAECs. Although maximum responses are noted at a high concentration of 100 nmol/L, low physiological concentrations of 1 and 10 nmol/L stimulated significant concentration-dependent increases of PGI 2 and PGI 2 /TXA 2 ratios more in P-UAECs than in NP-UAECs. In support of these findings are reports that E 2 β induces production of PGI 2 in other cultured endothelial cells such as HUVECs, bovine pulmonary artery, and aortic endothelial cells. 14, [23] [24] [25] We have previously reported that the infusion of E 2 β in sheep significantly increases the ex vivo uterine arterial production of the stable PGI 2 metabolite 6-keto-PGF1α. 21 However, to the best of our knowledge, this is the first study to evaluate the in vitro comparison with E 2 β-induced uterine endothelial PGI 2 production and elevated PGI 2 /TXA 2 ratios in the pregnant versus the nonpregnant states. In this regard, these data are also consistent with our previous findings that P-UAECs exhibit pregnancy-specific PGI 2 production in response to ATP, basic fibroblast growth factor, and epidermal growth factor. 6 Our findings that 2-OHE 2 and 4-OHE 2 stimulate increases of PGI 2 and PGI 2 /TXA 2 ratios more in P-UAECs than in NP-UAECs support our hypothesis that cytochrome P450-derived metabolites of E 2 β may play a role in the regulation of vascular responsiveness during pregnancy. It has been previously demonstrated that the uterine arterial infusion of 2-OHE 2 and 4-OHE 2 in sheep and gilts causes vasodilation and increases in uterine blood flow.
26,27 2-OHE 2 and 4-OHE 2 also significantly augment endothelial-dependent vasodilation of preconstricted vascular beds in ZSF1 rats, an animal model for hypertension, type 2 diabetes mellitus, hyperlipidemia, nephropathy, and metabolic syndrome. 16, 28 Because 2-OHE 2 and 4-OHE 2 are rapidly converted to their methoxy derivatives in the presence of catechol-O-methyltransferase, it is likely that the actions of the catecholestradiols on endothelial PGI 2 / TXA 2 ratios maybe partly modulated by catechol-O-methyltransferase expression and activity in these endothelial cells. Nevertheless, these observations suggest that the metabolism of E 2 β to the catecholestradiols, 2-OHE 2 and 4-OHE 2 , may also play an essential role in the regulation of physiological vascular responsiveness via production of endothelial-derived vasodilatory factors.
The observation that 2-ME 2 and 4-ME 2 enhance PGI 2 levels and PGI 2 /TXA 2 ratios in P-UAECs more than in NP-UAECs supports evidence that methoxyestradiols may positively influence vascular responsiveness during pregnancy. Consistent with these findings is the report that 2-ME 2 induces PGI 2 production in HUVECs.
19 Low 2-ME 2 level has been implicated in preeclampsia, a disease characterized by low plasma and urinary PGI 2 and impaired uterine blood flow. 29, 30 These observations suggest that 2-ME 2 may be a promising physiological as well as pharmacological agent capable of clinically improving vascular responsiveness. We demonstrate for the first time that 4-ME 2 also stimulates in vitro PGI 2 increases greater in the pregnant compared with the nonpregnant state and indeed may play a role in positive pregnancy-induced uterine vascular responsiveness. Because 2-ME 2 and 4-ME 2 induced higher PGI 2 increases at very low physiologic concentrations compared to E 2 β and the catecholestradiols, this suggests that the methoxyestradiols maybe more potent under these conditions and points to the notion that the vascular effects of locally produced or even circulating estrogen metabolites may be more critical than previously thought compared to the effects of the parent substrate.
Demonstrating a role for ER-α and ER-β, ICI 182,780, which nonspecifically blocks both ER-α and ER-β, completely abrogated the E 2 β-induced PGI 2 production in P-UAECs. Previous studies have demonstrated that ICI 182,780 also inhibits E 2 β-induced production of PGI 2 in other cultured endothelial cells, including HUVECs and ovine fetal pulmonary artery endothelial cells.
14 However, because of the potential relevance of ER subtype selectivity in vascular function, there is considerable interest in investigating whether the classical ERs exhibit functional heterogeneity in the regulation of E 2 β-induced endothelial functions. Our data show that E 2 β-induced PGI 2 increases in P-UAECs are completely inhibited by the ER-α-specific MPP and unaffected by ER-β-specific PHTPP, demonstrating that E 2 β-induced PGI 2 production in P-UAECs is primarily mediated by ER-α. These data are in agreement with previous observations that PGI 2 production by HUVECs was seen when these cells were treated with an ER-α-selective agonist 4,4′,4″-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol.
14 These data also support the notion that whereas E 2 β binds and activates both ER-α and ER-β, it is the molecular and structural-based differences in these receptors that allow for a wide range of functional heterogeneity, which may partly explain the selective actions of E 2 β.
In the present study, unlike E 2 β, the effects of its metabolites on PGI 2 production by P-UAECs are not inhibited by the ER antagonists used in this study and thus are not mediated via ER-α and ER-β. This is in agreement with several reports that the vascular physiology and pharmacology of E 2 β metabolites on many cell types, including endothelial cells, occur via ER-independent mechanisms. [16] [17] [18] Thus, other receptor-mediated mechanisms not involving the classical ERs may mediate E 2 β metabolites-induced PGI 2 production in P-UAECs. Indeed we and others have reported that the genomic effects of E 2 β metabolites, including proliferation of P-UAECs and suppression of pancreatic islet insulin release, are mediated via the adrenergic receptors. 18, 31 Nevertheless, the exact mechanism of action of E 2 β metabolites on nongenomic PGI 2 increases in P-UAECs remains to be determined and may likely involve adrenergic receptors and other estrogen-associated receptors like G protein-coupled receptor-30.
In conclusion, the findings from this current study demonstrate that the uterine endothelium exhibits pregnancy-specific increases in cPLA 2 , COX-1, and PGIS and decreases in TXAS shifting in the endothelial PGI 2 /TXA 2 ratios toward more PGI 2 production in association with rises and maintenance of uterine blood flow during pregnancy. Furthermore, we provide evidence that E 2 β primarily via ER-α and its metabolites via ER-independent mechanisms stimulate a higher de novo increases of the endothelial-derived vasodilator PGI 2 and PGI 2 /TXA 2 ratios in the pregnant compared with the nonpregnant state. Although maximum production of PGI 2 and the PGI 2 /TXA 2 ratio was noted with the high concentration of 100 nmol/L, low physiologically relevant concentrations of 1 and 10 nmol/L of E 2 β and its metabolites also stimulated significant synthesis of these prostanoids more in P-UAECs compared with NP-UAECs. Collectively, the selective responses of P-UAECs further illustrate pregnancy-specific programming at the level of the uterine artery endothelium signaling, resulting in enhanced E 2 β and its metabolites-mediated induction of PGI 2 synthesis in P-UAECs without significantly affecting TXA 2 production.
Perspectives
The mechanisms by which estrogens regulate vascular tone and vascular responsiveness during pregnancy are not well understood. However, studies have shown that it likely involves ER-mediated stimulation of endothelial-derived vasodilatory factors including NO and PGI 2 .
1,11 Herein, we demonstrate novel and compelling evidence that the vasoactive/vasoprotective effects of E 2 β during pregnancy may also involve its sequential conversion to catecholestradiols and methoxyestradiols, which are capable of stimulating ER-independent endothelial PGI 2 synthesis. Additional studies are required to understand whether the ER-independent induction of endothelial PGI 2 synthesis by estrogen metabolites within uterine vasculature represents unappreciated signaling complexity of estrogens or just simply an evolutionary functional redundancy to maintain uterine blood flow and thus oxygen and nutrient delivery during gestation. Nevertheless, our findings necessitate the evaluation of catecholestradiols and methoxyestradiols in the regulation of vascular tone in physiology via endothelial-derived relaxing factors, as well as dysregulation in the pathophysiology of vascular diseases, such as hypertension, atherosclerosis, and gestational vascular diseases, such as preeclampsia.
